Skip to content

Clinical trials

Completed Observational Diabetes Mellitus, Type 1 trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Diabetes Mellitus, Type 1 Phase: Observational Status: Completed Clear all

459 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20013
20024
20035
200412
200513
200617
200719
200825
200918
201014
201115
201224
201323
201417
201520
201621
201716
201830
201917
202033
202134
202226
202322
202411
202513
20261

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed459

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Novo Nordisk A/S73
Castilla-La Mancha Health Service10
University of Colorado, Denver9
Centre Hospitalier Sud Francilien8
University of Ljubljana, Faculty of Medicine6
University of Virginia6
Yale University6
Jaeb Center for Health Research5
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)5
Steno Diabetes Center Copenhagen5

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Diabetes Mellitus, Type 1459
Diabetes Mellitus127
Diabetes Mellitus, Type 2120
Hypoglycemia23
Insulin Resistance14
Hyperglycemia11
Cardiovascular Diseases8
Autoimmune Diseases7
COVID-197
Diabetes Complications6

Trials

Showing 1 to 25 of 459. Each trial links to its page on Pharma Observatory.

359 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.